PET Imaging Agent Identifies Recurrent Prostate Cancer
|
By MedImaging International staff writers Posted on 07 Apr 2017 |
|
Image: A PET scan of recurrent prostate tumor with fluciclovine (L) compared to indium-111 (R) in same region (Photo courtesy of Radiology).
A diagnostic agent for positron emission tomography (PET) imaging can help identify suspected sites of prostate cancer recurrence.
Axumin (fluciclovine) is a synthetic L-leucine analogue radiolabeled with fluorine 18 (18F), which enters cells via amino acid transporters. Since tumor cells exhibit enhanced amino acid transport in order to help them access the materials they need to grow and spread, they take up Axumin more than healthy tissues, providing physicians with a better tool for locating recurrent prostate cancer sites, based on a detected rise in the levels of prostate specific antigen (PSA) following initial therapy.
Axumin has a short synthesis time and a long half-life, which eliminate the need for an onsite cyclotron during the PET scan. The distribution of Axumin in the body also differs from other tracers, with a low native brain uptake compared to Fludeoxyglucose (FDG). Axumin is a product of Blue Earth Diagnostics, and has been approved by the European Medicines Agency (EMA) and the U.S. Food and Drug Administration (FDA).
“An imaging agent with sufficient diagnostic performance to adequately detect and localize recurrent prostate cancer can provide referring physicians with actionable information to guide biopsy, and inform management decisions for their patients,” said David Schuster, MD, director of the division of nuclear medicine and molecular imaging at Emory University (Atlanta, GA, USA). “The product will be convenient for patients and imaging facilities, as it can be made widely available and the entire imaging procedure can typically be completed in less than 30 minutes.”
A variety of imaging techniques and tests are currently used to diagnose and monitor prostate cancer, including PSA blood tests, magnetic resonance imaging (MRI), PET, SPECT, and CT scans. Each method has strengths and weaknesses, but there is no single method that is able to successfully identify and monitor primary tumors, metastatic lymph nodes, and bone lesions, which can cause the patient to undergo unnecessary treatments or painful biopsies.
Axumin (fluciclovine) is a synthetic L-leucine analogue radiolabeled with fluorine 18 (18F), which enters cells via amino acid transporters. Since tumor cells exhibit enhanced amino acid transport in order to help them access the materials they need to grow and spread, they take up Axumin more than healthy tissues, providing physicians with a better tool for locating recurrent prostate cancer sites, based on a detected rise in the levels of prostate specific antigen (PSA) following initial therapy.
Axumin has a short synthesis time and a long half-life, which eliminate the need for an onsite cyclotron during the PET scan. The distribution of Axumin in the body also differs from other tracers, with a low native brain uptake compared to Fludeoxyglucose (FDG). Axumin is a product of Blue Earth Diagnostics, and has been approved by the European Medicines Agency (EMA) and the U.S. Food and Drug Administration (FDA).
“An imaging agent with sufficient diagnostic performance to adequately detect and localize recurrent prostate cancer can provide referring physicians with actionable information to guide biopsy, and inform management decisions for their patients,” said David Schuster, MD, director of the division of nuclear medicine and molecular imaging at Emory University (Atlanta, GA, USA). “The product will be convenient for patients and imaging facilities, as it can be made widely available and the entire imaging procedure can typically be completed in less than 30 minutes.”
A variety of imaging techniques and tests are currently used to diagnose and monitor prostate cancer, including PSA blood tests, magnetic resonance imaging (MRI), PET, SPECT, and CT scans. Each method has strengths and weaknesses, but there is no single method that is able to successfully identify and monitor primary tumors, metastatic lymph nodes, and bone lesions, which can cause the patient to undergo unnecessary treatments or painful biopsies.
Gold Member
Solid State Kv/Dose Multi-Sensor
AGMS-DM+
Ultrasound Needle Guide
Ultra-Pro II
New
Ultrasound System
P20 Elite
New
Illuminator
Trimline Basic
Latest Radiography News
- Novel Breast Imaging System Proves As Effective As Mammography
- AI Assistance Improves Breast-Cancer Screening by Reducing False Positives
- AI Could Boost Clinical Adoption of Chest DDR
- 3D Mammography Almost Halves Breast Cancer Incidence between Two Screening Tests
- AI Model Predicts 5-Year Breast Cancer Risk from Mammograms
- Deep Learning Framework Detects Fractures in X-Ray Images With 99% Accuracy
- Direct AI-Based Medical X-Ray Imaging System a Paradigm-Shift from Conventional DR and CT
- Chest X-Ray AI Solution Automatically Identifies, Categorizes and Highlights Suspicious Areas
- AI Diagnoses Wrist Fractures As Well As Radiologists
- Annual Mammography Beginning At 40 Cuts Breast Cancer Mortality By 42%
- 3D Human GPS Powered By Light Paves Way for Radiation-Free Minimally-Invasive Surgery
- Novel AI Technology to Revolutionize Cancer Detection in Dense Breasts
- AI Solution Provides Radiologists with 'Second Pair' Of Eyes to Detect Breast Cancers
- AI Helps General Radiologists Achieve Specialist-Level Performance in Interpreting Mammograms
- Novel Imaging Technique Could Transform Breast Cancer Detection
- Computer Program Combines AI and Heat-Imaging Technology for Early Breast Cancer Detection
Channels
MRI
view channel
World's First Whole-Body Ultra-High Field MRI Officially Comes To Market
The world's first whole-body ultra-high field (UHF) MRI has officially come to market, marking a remarkable advancement in diagnostic radiology. United Imaging (Shanghai, China) has secured clearance from the U.... Read more
World's First Sensor Detects Errors in MRI Scans Using Laser Light and Gas
MRI scanners are daily tools for doctors and healthcare professionals, providing unparalleled 3D imaging of the brain, vital organs, and soft tissues, far surpassing other imaging technologies in quality.... Read more
Diamond Dust Could Offer New Contrast Agent Option for Future MRI Scans
Gadolinium, a heavy metal used for over three decades as a contrast agent in medical imaging, enhances the clarity of MRI scans by highlighting affected areas. Despite its utility, gadolinium not only... Read more.jpg "Image: The emerging role of MRI alongside PSA testing is redefining prostate cancer diagnostics (Photo courtesy of 123RF)")
Combining MRI with PSA Testing Improves Clinical Outcomes for Prostate Cancer Patients
Prostate cancer is a leading health concern globally, consistently being one of the most common types of cancer among men and a major cause of cancer-related deaths. In the United States, it is the most... Read moreUltrasound
view channel
First AI-Powered POC Ultrasound Diagnostic Solution Helps Prioritize Cases Based On Severity
Ultrasound scans are essential for identifying and diagnosing various medical conditions, but often, patients must wait weeks or months for results due to a shortage of qualified medical professionals... Read more
Largest Model Trained On Echocardiography Images Assesses Heart Structure and Function
Foundation models represent an exciting frontier in generative artificial intelligence (AI), yet many lack the specialized medical data needed to make them applicable in healthcare settings.... Read more.jpg "Image: The Sonic Lumen Tomography (SLT) intravascular ultrasound system has received FDA 510(k) clearance (Photo courtesy of Provisio Medical)")
Groundbreaking Technology Enables Precise, Automatic Measurement of Peripheral Blood Vessels
The current standard of care of using angiographic information is often inadequate for accurately assessing vessel size in the estimated 20 million people in the U.S. who suffer from peripheral vascular disease.... Read more
Nuclear Medicine
view channel
New Imaging Technique Monitors Inflammation Disorders without Radiation Exposure
Imaging inflammation using traditional radiological techniques presents significant challenges, including radiation exposure, poor image quality, high costs, and invasive procedures. Now, new contrast... Read more
New SPECT/CT Technique Could Change Imaging Practices and Increase Patient Access
The development of lead-212 (212Pb)-PSMA–based targeted alpha therapy (TAT) is garnering significant interest in treating patients with metastatic castration-resistant prostate cancer. The imaging of 212Pb,... Read more
New Radiotheranostic System Detects and Treats Ovarian Cancer Noninvasively
Ovarian cancer is the most lethal gynecological cancer, with less than a 30% five-year survival rate for those diagnosed in late stages. Despite surgery and platinum-based chemotherapy being the standard... Read more
AI System Automatically and Reliably Detects Cardiac Amyloidosis Using Scintigraphy Imaging
Cardiac amyloidosis, a condition characterized by the buildup of abnormal protein deposits (amyloids) in the heart muscle, severely affects heart function and can lead to heart failure or death without... Read moreGeneral/Advanced Imaging
view channel
Radiation Therapy Computed Tomography Solution Boosts Imaging Accuracy
One of the most significant challenges in oncology care is disease complexity in terms of the variety of cancer types and the individualized presentation of each patient. This complexity necessitates a... Read more
PET Scans Reveal Hidden Inflammation in Multiple Sclerosis Patients
A key challenge for clinicians treating patients with multiple sclerosis (MS) is that after a certain amount of time, they continue to worsen even though their MRIs show no change. A new study has now... Read more
Imaging IT
view channel
New Google Cloud Medical Imaging Suite Makes Imaging Healthcare Data More Accessible
Medical imaging is a critical tool used to diagnose patients, and there are billions of medical images scanned globally each year. Imaging data accounts for about 90% of all healthcare data1 and, until... Read more
Global AI in Medical Diagnostics Market to Be Driven by Demand for Image Recognition in Radiology
The global artificial intelligence (AI) in medical diagnostics market is expanding with early disease detection being one of its key applications and image recognition becoming a compelling consumer proposition... Read more
Industry News
view channel
Hologic Acquires UK-Based Breast Surgical Guidance Company Endomagnetics Ltd.
Hologic, Inc. (Marlborough, MA, USA) has entered into a definitive agreement to acquire Endomagnetics Ltd. (Cambridge, UK), a privately held developer of breast cancer surgery technologies, for approximately... Read more
Bayer and Google Partner on New AI Product for Radiologists
Medical imaging data comprises around 90% of all healthcare data, and it is a highly complex and rich clinical data modality and serves as a vital tool for diagnosing patients. Each year, billions of medical... Read more
